Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | BAX | Q07812 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5697493 | 0.77 | MRGPRX1 (0.45) | MRGPRX1 | |
| SCHEMBL17010926 | 0.77 | LTA4H (0.50) | LTA4HTSHRTDP1L3MBTL1CA4 | |
| SCHEMBL12168393 | 0.75 | GUSB (0.33) | SMN1; SMN2 | |
| SCHEMBL10950997 | 0.74 | LTA4H (0.46) | LTA4HTSHRNR1H2BAXMAOA | |
| SCHEMBL20708903 | 0.74 | MAOA (0.46) | LTA4HTSHRNR1H2BAXMAOA | |
| SCHEMBL5697484 | 0.74 | LTA4H (0.46) | LTA4HTSHRTDP1L3MBTL1PPARG | |
| SCHEMBL923385 | 0.74 | LTA4H (0.41) | LTA4HTSHRTDP1L3MBTL1PPARG | |
| SCHEMBL922635 | 0.69 | CYP2E1 (0.48) | LTA4HTSHRMAOA | |
| SCHEMBL6489226 | 0.69 | MEN1 (0.46) | LTA4HTSHR | |
| SCHEMBL12351794 | 0.69 | LTA4H (0.41) | LTA4HTSHRPPARGNR1H2BAX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10727534-B2 | Electrolyte solution containing magnesium ions | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2020-07-28 | — | — | US | disclosed |
| US-20190131657-A1 | ELECTROLYTE SOLUTION CONTAINING MAGNESIUM IONS | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2019-05-02 | — | — | US | disclosed |
| EP-1669348-A1 | NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10727534-B2 | Electrolyte solution containing magnesium ions | MLX, PRDX1, PRDX6 | LTA4H 2785/4885TSHR 2008/4885TDP1 2910/4885 |
| US-20190131657-A1 | ELECTROLYTE SOLUTION CONTAINING MAGNESIUM IONS | MLX, PRDX1, PRDX6 | LTA4H 2785/4885TSHR 2008/4885TDP1 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.